← Eichor
Study identifier: NCT06786819 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Impact of a Technology Platform Based on Enhanced Recovery After(ERAS) Surgery on Length of Stay After Coronary Artery Bypass Grafting: Timely Project

Condition: ERAS · Cardiac Surgery · Cardiac Surgery-CABG  ·  Sponsor: University of Sao Paulo General Hospital

PhaseNA
Planned participants480
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cardiovascular diseases continue to be the leading cause of death worldwide. Among them, coronary artery disease has the greatest impact, being characterized as one of the main causes of death in Brazil over the last decade. One of the well-established treatments is coronary artery bypass grafting, which is the most performed among cardiac surgeries and, in our scenario, is primarily funded by the Unified Health System (SUS). The information obtained from the Paulista Registry of Cardiovascular Surgeries (REPLICCAR), in partnership with FAPESP, has been important for implementing improvements in the landscape of cardiac surgeries in the state of São Paulo. Although outcomes in cardiac surgery have improved due to the structuring and organization of quality programs, this is still not a reality at the national level. In a situation where data collection and quality initiatives play a central role in continuous improvement, generating value becomes essential for the sustainability of cardiac surgery programs. In this sense, the concept of Enhanced Recovery After Surgery (ERAS) has gained increasing traction. This concept is based on multidisciplinary protocols and scientific evidence, which help prepare patients for rapid recovery, resulting in reduced complications, shorter hospital stays, and, primarily, lower hospital costs. On the other hand, the increase in surgical waiting lists has also led to a rise in home mortality due to cardiac causes. Thus, among the various challe…

This description comes directly from the study's public registry record.

Talk to the study team

Omar A V Mejia, MD, PhD  ·  +551126615014  ·  omar.mejia@incor.usp.br

Gabrielle B Borgomoni, BSc, PhD student  ·  +551126615014  ·  gbborgomoni-biomedicina@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

InCor - Instituto do Coração do Hospital das Clínicas da FMUSPSão Paulo, São Paulo, BrazilRecruiting
InCor - Instituto do Coração do Hospital das Clínicas da FMUSPSão Paulo, São Paulo, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06786819